Curis (NASDAQ:CRIS) Price Target Lowered to $20.00 at HC Wainwright

Curis (NASDAQ:CRIS) had its price objective lowered by HC Wainwright from $26.00 to $20.00 in a report published on Friday, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Curis Price Performance

CRIS traded down $0.10 during mid-day trading on Friday, hitting $4.18. The stock had a trading volume of 40,502 shares, compared to its average volume of 37,330. Curis has a 1-year low of $4.05 and a 1-year high of $17.49. The firm has a market capitalization of $25.00 million, a price-to-earnings ratio of -0.51 and a beta of 3.32. The stock’s fifty day simple moving average is $5.28 and its 200-day simple moving average is $7.86.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($2.03) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.36). The business had revenue of $2.55 million for the quarter, compared to the consensus estimate of $2.20 million. Curis had a negative net margin of 468.18% and a negative return on equity of 327.92%. During the same quarter last year, the firm earned ($2.40) EPS. As a group, research analysts expect that Curis will post -6.79 earnings per share for the current fiscal year.

Institutional Trading of Curis

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after buying an additional 10,097 shares during the last quarter. CM Management LLC lifted its position in shares of Curis by 380.0% in the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 95,000 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after purchasing an additional 96,256 shares during the last quarter. Finally, Focused Wealth Management Inc grew its position in Curis by 63.1% in the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 20,908 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.